Quick Takeaways
- Redmile Group, LLC filed SCHEDULE 13G/A for Amicus Therapeutics, Inc. Common Stock, par value $0.01 per share (FOLD).
- Disclosed ownership: 4.6%.
- Date of event: 31 Dec 2024.
Redmile Group, LLC - 31 Dec 2024 SCHEDULE 13G/A Report for Amicus Therapeutics, Inc. Common Stock, par value $0.01 per share (FOLD)
- Filing Manager
- Redmile Group, LLC
- Reporting Manager
- Redmile Group, LLC
- Symbol
- FOLD
- Shares outstanding
- 308,358,587 shares
- Disclosed Ownership
- 14,184,495 shares
- Ownership
- 4.6%
- Form type
- SCHEDULE 13G/A
- Filing time
- 14 Feb 2025, 20:00:35 UTC
- Date of event
- 31 Dec 2024
- SEC
- View on sec.gov
Quoteable Key Fact
"Redmile Group, LLC disclosed 4.6% ownership in Amicus Therapeutics, Inc. Common Stock, par value $0.01 per share (FOLD) on 31 Dec 2024."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 Feb 2025, 20:00.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Redmile Group, LLC | 4.6% | 14,184,495 | 0 | 14,184,495 | /s/ Jeremy C. Green | Managing Member | |
| Jeremy C. Green | 4.6% | 14,184,495 | 0 | 14,184,495 | /s/ Jeremy C. Green | Jeremy C. Green |